Cambridge, MA-based ImmunoGen (NASDAQ: IMGN) has snagged a $1.5 million milestone payment from Biogen Idec (NASDAQ: BIIB), the latest in a string of positive signs for a company that has struggled for decades, as David described last week. The payment was triggered by Biogen filing for FDA permission to being clinical trials of an anti-tumor agent that combines the two companies’ technologies.
Why is this story so short? Because it's a news brief from our News Xpress section, which brings you quick takes on the latest Boston-area biz/tech news as it unfolds throughout the day.
Where do I find more in-depth news and analysis about the business of technology in the Boston area? We've got plenty of that right on our home page and in our archives.
Who the heck are the Xconomists mentioned on your homepage? They're an elite group of movers and shakers in the local tech scene who've generously agreed to share their insights and opinions with Xconomy's readers. Here's a complete list of them; to read their posts, have a look here and here.
Come to think of it, what does "Xconomy" mean in the first place? Xconomy is a word we made up to evoke the exponential economy—the realm of business and innovation characterized by exponential technological growth and responsible for an increasing share of productivity and overall economic growth. (Not everybody likes the name, by the way. We're okay with that.) We're a small group of professional journalists dedicated to bringing you the most important news about New England's role in the exponential economy. More on our mission and team here.
© 2007 Xconomy. All rights reserved. Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.
Share
